The race to grab market share in the migraine space is becoming one of the most keenly-watched in pharma – and Aimovig (erenumab) is forecast to be the top-selling drug by 2026. 23 October 2018
Japanese pharma company Eisai announced with partner Meiji Seika that an application seeking manufacturing and marketing approval in Japan was submitted as of today by Meiji for the Parkinson’s disease treatment ME2125 (safinamide mesylate). 23 October 2018
Danish CNS specialist Lundbeck and its partner Takeda Pharmaceuticals can once again expand the clinical trials section of the US label of their antidepressant Trintellix (vortioxetine). 22 October 2018
Japan’s Eisai and partner Purdue Pharma today released positive top-line results from SUNRISE 2, a long-term Phase III efficacy and safety evaluation of lemborexant, an investigational agent for sleep-wake regulation currently being studied for the potential treatment of multiple sleep-wake disorders. 17 October 2018
Intrathecal catheterization is a highly effective delivery method for drugs targeting neurological diseases, writes Brad Gien, head of surgery, North America, Envigo, in an Expert View piece. 17 October 2018
Israeli drugmaker Teva Pharmaceutical Industries looks likely to see declining sales of its leading multiple sclerosis drug Copaxone (glatiramer acetate) plummet further following a court ruling on Friday. 15 October 2018
Germany’s Probiodrug (AMS: PBD) announced to the stock market that a cumulative loss of more than half of the nominal share capital of the company has been incurred, due to operating losses resulting from ordinary business operations. 15 October 2018
Israeli drugmaker Teva Pharmaceutical Industries is already facing a hit to its revenue from generic competition to Copaxone (glatiramer acetate). 11 October 2018
German biotech Evotec today revealed that it will receive a $6 million payment from Celgene following Celgene's decision to expand the collaboration to include additional cell lines. 11 October 2018
Swedish startup Lobsor has won its first approval for Lecigon (levodopa/carbidopa/entacapone), a new therapeutic system for symptomatic treatment of advanced Parkinson’s disease, a decision which could shake up a market dominated by AbbVie. 10 October 2018
The Russian government plans to provide access to imported drugs that have not undergone clinical trials within Russia, according to recent statements by some senior officials of the Russian Ministry of Health. 10 October 2018
Over the past 24 months, the Latin American cannabis industry has emerged from the shadows to command the attention of the international cannabis community as over ten major markets have legalized medical cannabis. 8 October 2018
Shares in Australian biotech firm Bionomics crashed on Tuesday, dropping more than 60% after the firm released disappointing top-line data from a Phase II study of BNC210. 3 October 2018
Eli Lilly has just received US Food and Drug Administration (FDA) approval with its entry into the emerging class of CGRP-inhibitor migraine drugs. 28 September 2018
The US Drug Enforcement Administration (DEA) has given the nod for GW Pharmaceuticals to retail its cannabis-based therapy Epidiolex (cannabidiol), just three months after it was approved by the US regulator. 28 September 2018
The US Congress has agreed on a wide-ranging bill aimed at tackling the burgeoning epidemic of opioids abuse in the country, while rejecting a pharma industry amendment that would have reduced drugmakers' share of medicine costs under Medicare. 27 September 2018
Privately-held US firm Tris Pharma today announced the acquisition of NextWave Pharmaceuticals, a wholly-owned subsidiary of Pfizer, including two key attention deficit hyperactivity disorder (ADHD) treatments. 25 September 2018
Today, the US Food and Drug Administration approved Miplyffa (arimoclomol), an oral medication for the treatment of Neimann-Pick disease, type C (NPC). 20 September 2024
US neuroscience company BioXcel Therapeutics has announced a new clinical prioritization and an update on its late-stage development programs for the treatment of agitation with BXCL501. 20 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US clinical stage CNS drug developer Athira Pharma is taking decisive action following the company’s announcement of disappointing data from the Phase II/III LIFT-AD clinical trial of fosgonimeton to treat Alzheimer’s disease (AD). 18 September 2024
The US Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), from Swiss pharma giant Roche. 16 September 2024
US pharma major Eli Lilly has announced a $1 billion expansion of its manufacturing site in Limerick, Ireland, to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease. 13 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
The global migraine market in mature economies is projected to grow from $9.2 billion in 2023 to $16.4 billion by 2033, according to a report from GlobalData. 10 September 2024
Cartesian Therapeutics today announced that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM). 9 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
The cost of prescribed dependency-forming medicines has decreased by £410 million ($539.6 million) since 2015/16, according to newly released data from the UK’s National Health Service (NHS). 6 September 2024
Shares in US biopharma Axsome Therapeutics, a biopharmaceutical company developing and delivering novel therapies for the management of CNS disorders, closed 7% higher on Wednesday. 5 September 2024
Mid-Atlantic BioTherapeutics (MABT) has announced a collaboration with Accelero Biostructures to identify novel inhibitors of USP30, a protein linked to neurological disorders and other conditions. 5 September 2024
Praxis Precision Medicines shared positive top-line results for its Phase II, proof of concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathy (DEE) patients. 4 September 2024